阿卡波糖联合优泌乐25R治疗初诊2型糖尿病患者疗效观察  

Clinical observation of Acarbose combined with Humalog 25R in the treatment of patients with newly diagnosed type 2 diabetes

作　　者：赵弋于[1] 

机构地区：[1]广西民族医院内分泌科,南宁530001

出　　处：《中国临床新医学》2012年第2期119-121,共3页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

摘　　要：目的探讨阿卡波糖联合优泌乐25R治疗初诊2型糖尿病患者的临床疗效。方法选择80例初诊2型糖尿病患者随机分为治疗组(阿卡波糖联合优泌乐25R)40例,对照组(阿卡波糖联合磺脲类降糖药)40例,疗程12周,分别检测治疗前后空腹血糖、餐后2 h血糖、糖化血红蛋白、空腹C肽、餐后2 h C肽,观察血糖达标时间、低血糖发生率,并进行比较。结果与对照组比较,治疗组低血糖发生率较低(P<0.05),糖化血红蛋白明显下降(P<0.01),胰岛β细胞功能明显提高(P<0.05)。结论阿卡波糖联合优泌乐25R是初诊2型糖尿病患者理想的治疗方案。Objective To explore the efficacy of Acarbose combined with Humalog 25R in the treatment of patients with newly diagnosed type 2 diabetes. Methods Eighty patients with newly diagnosed type 2 diabetes were randomly divided into treatment group （Acarbose combined with Humalog 25R） and control group （Acarbose combined with sulfonylurea drugs）, 40 cases in each group, with 12 weeks of treatment. Before and after treatment, fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin, fasting C-peptide, 2-hour postprandial C- peptide, blood glucose standard time, the incidence of hypoglycemia were measured and compared. Results Compared with control group, in the treatment group,the incidence of hypoglycemia was lower （P 〈 0.05 ）, the glycosylated hemoglobin decreased significantly （ P 〈 0. 01 ）, and the β-cell function improved significantly （ P 〈 0. 05 ）. Conclusion Acarbose combined with Humalog 25R is an ideal treatment option for patients with newly diagnosed type 2 diabetes.

关 键 词：阿卡波糖 优泌乐25R 初诊2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]